FibroBiologics Files Q1 2025 10-Q
Ticker: FBLG · Form: 10-Q · Filed: May 14, 2025 · CIK: 1958777
Sentiment: neutral
Topics: 10-Q, financials, stock-information
TL;DR
FibroBiologics Q1 2025 10-Q filed. Shows preferred and common stock details.
AI Summary
FibroBiologics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, located at 455 E. Medical Center Blvd, Suite 300, Houston, TX, reported its financial status. Key financial data points include Series C Preferred Stock and Voting Common Stock figures for both March 31, 2025, and December 31, 2024.
Why It Matters
This filing provides investors with the latest financial snapshot of FibroBiologics, Inc., detailing their capital structure and stock information as of the first quarter of 2025.
Risk Assessment
Risk Level: low — This filing is a routine quarterly report and does not contain new material events or significant financial distress indicators.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for this 10-Q filing.)
- 2024-12-31 — Prior Period End Date (Provides a comparative balance sheet date from the previous fiscal year-end.)
- 2024-03-31 — Prior Year Quarter End Date (Allows for year-over-year comparison of financial performance.)
Key Players & Entities
- FibroBiologics, Inc. (company) — Filer of the 10-Q report
- 20250331 (date) — End of the reporting period
- 455 E. MEDICAL CENTER BLVD SUITE 300 (address) — Company's business and mailing address
- HOUSTON (location) — City of the company's address
- TX (location) — State of the company's address
- 77598 (postal_code) — Zip code of the company's address
- 281-671-5150 (phone_number) — Company's business phone number
- 20221216 (date) — Date of former company name change
- 2025-01-01 (date) — Start of the reporting period
- 2025-03-31 (date) — End of the reporting period
FAQ
What is the primary business of FibroBiologics, Inc.?
FibroBiologics, Inc. is classified under Pharmaceutical Preparations [2834] according to its SIC code.
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the filing covers the first quarter of 2025.
Where is FibroBiologics, Inc. located?
The company's business address is 455 E. Medical Center Blvd, Suite 300, Houston, TX 77598.
What types of stock are specifically mentioned in the filing data?
The filing data mentions Series C Preferred Stock, Voting Common Stock, Series A Preferred Stock, Series B Preferred Stock, Series B-One Preferred Stock, and Nonvoting Common Stock.
When was the company's name last changed?
The former company name was FibroBiologics Inc., and the date of the name change was 20221216.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding FibroBiologics, Inc. (FBLG).